A new entity of abdominal squamous cell carcinoma of unknown primary

Rassy, Elie El; Kattan, Joseph; Pavlidis, Nicholas

doi:10.1111/eci.13111

Cited by 17 publications

(8 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CUP was divided into two subgroups according to their clinical and pathological conditions in traditional assessment (Pavlidis et al, 2003). For the first subgroup, 15-20% of patients showed specific clinical and pathological characteristics, which strongly indicate the origin of tumor tissue (El Rassy et al, 2019;Rassy et al, 2019;Rassy et al, 2020a). This part of CUP has chemosensitive tumors with good prognoses when treated with native treatments (Fizazi et al, 2015).…”

Section: Discussionmentioning

confidence: 99%

The diagnosis and treatment for a patient with cancer of unknown primary: A case report

Pan²,

Shen³

et al. 2023

Front. Genet.

View full text Add to dashboard Cite

Background: Cancer of unknown primary (CUP) is a class of metastatic malignant tumors whose primary location cannot be determined. The diagnosis and treatment of CUP are a considerable challenge for clinicians. Herein, we report a CUP case whose corresponding primary tumor sites were successfully identified, and the patient received proper treatment.Case report: In February 2022, a 74-year-old woman was admitted to the Medical Oncology Department at Sir Run Run Shaw Hospital for new lung and intestinal tumors after more than 9 years of breast cancer surgery. After laparoscopically assisted right hemicolectomy, pathology revealed mucinous adenocarcinoma; the pathological stage was pT2N0M0. Results from needle biopsies of lung masses suggested poorly differentiated cancer, ER (-), PR (-), and HER2 (-), which combined with the clinical history, did not rule out metastatic breast cancer. A surgical pathology sample was needed to determine the origin of the tumor tissue, but the patient’s chest structure showed no indications for surgery. Analysis of the tumor’s traceable gene expression profile prompted breast cancer, and analysis of next-generation amplification sequencing (NGS) did not obtain a potential drug target. We developed a treatment plan based on comprehensive immunohistochemistry, a gene expression profile, and NGS analysis. The treatment plan was formulated using paclitaxel albumin and capecitabine in combination with radiotherapy. The efficacy evaluation was the partial response (PR) after four cycles of chemotherapy and two cycles combined with radiotherapy.Conclusion: This case highlighted the importance of identifying accurate primary tumor location for patients to benefit from treatment, which will provide a reference for the treatment decisions of CUP tumors in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

The diagnosis and treatment for a patient with cancer of unknown primary: A case report

Pan²,

Shen³

et al. 2023

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…1 For the treatment of pelvic CUP-SCC, concurrent chemoradiotherapy (CCRT) is the most common strategy; however, its efficacy varies among individuals. 4 The cancer genomic profile (CGP) test is widely used to identify actionable genomic alterations and elucidate the pathogenesis of various cancers. 5 These genomic approaches are used for identifying druggable mutations of CUPs 3,6 ; however, only a small proportion of patients receive these molecular target therapies due to a lack of clinical trials.…”

Section: Introductionmentioning

confidence: 99%

A case of refractory pelvic squamous cell carcinoma of unknown primary that responded to nivolumab

Komura

Taguchi

Ikemura

et al. 2023

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Cancer of unknown primary (CUP) is a heterogeneous group of metastatic tumors with a usually unfavorable prognosis. A 33‐year‐old female was diagnosed with pelvic squamous cell carcinoma of unknown primary. The tumor was p16‐positive, suggesting that it was human papillomavirus (HPV)‐related. The tumor progressed for 4 months after concurrent chemoradiotherapy (initial treatment) and was refractory to paclitaxel plus carboplatin (second‐line therapy). Liquid‐based cancer genomic profiling identified five pathogenic variants, including Neurofibromin1 (NF1) (p.T1690Mfs*5); however, due to the lack of domestic clinical trials, the patient could not receive genome‐based molecular‐target therapies. Simultaneously, nivolumab was administered to the patient post its approval in Japan for CUP. The tumor responded to nivolumab, accompanied by decreased levels of tumor markers. NF1 mutations and HPV‐related carcinogenesis may be associated with a favorable response to nivolumab treatment. It may therefore serve as a potential treatment against cancers of unknown primaries.

show abstract

“…Familial clustering studies reported an increased risk of CUP in first-degree relatives, which is also associated with the occurrence of other types of tumors (lung, kidney, liver, ovarian, colorectal, breast, and melanoma) [11,12]. Other risk factors identified so far include smoking habits [8] and human papillomavirus (HPV) infection for squamous cell CUPs [13,14].…”

Section: Introductionmentioning

confidence: 99%

Cancer of Unknown Primary: Challenges and Progress in Clinical Management

Laprovitera

Riefolo

Ambrosini

et al. 2021

Cancers

View full text Add to dashboard Cite

Distant metastases are the main cause of cancer-related deaths in patients with advanced tumors. A standard diagnostic workup usually contains the identification of the tissue-of-origin of metastatic tumors, although under certain circumstances, it remains elusive. This disease setting is defined as cancer of unknown primary (CUP). Accounting for approximately 3–5% of all cancer diagnoses, CUPs are characterized by an aggressive clinical behavior and represent a real therapeutic challenge. The lack of determination of a tissue of origin precludes CUP patients from specific evidence-based therapeutic options or access to clinical trial, which significantly impacts their life expectancy. In the era of precision medicine, it is essential to characterize CUP molecular features, including the expression profile of non-coding RNAs, to improve our understanding of CUP biology and identify novel therapeutic strategies. This review article sheds light on this enigmatic disease by summarizing the current knowledge on CUPs focusing on recent discoveries and emerging diagnostic strategies.

show abstract

A new entity of abdominal squamous cell carcinoma of unknown primary

Cited by 17 publications

References 34 publications

The diagnosis and treatment for a patient with cancer of unknown primary: A case report

The diagnosis and treatment for a patient with cancer of unknown primary: A case report

A case of refractory pelvic squamous cell carcinoma of unknown primary that responded to nivolumab

Cancer of Unknown Primary: Challenges and Progress in Clinical Management

Contact Info

Product

Resources

About